Stephen MacMillan joined a struggling Hologic (NSDQ:HOLX) as CEO in December 2013, and within one day, he had already made his first major move in restructuring the company’s executive leadership team.
MacMillan spoke in a keynote presentation at Device Talks Boston yesterday about his entry into the women’s healthcare market with Hologic, how his turn-around of the company included removing executives at the firm and the importance of women’s health and comfort in medtech.
In considering the overall health of a team, MacMillan said that removing the bad players is as important, if not more, than adding positive talent.
During his first 14 months in the corner office, MacMillan said that he removed 24 of the 25 execs that were on board when he joined. The one executive he didn’t remove, Karleen Oberton, was promoted to chief financial officer this August, MacMillan said.